News-Medical.Net

Food timing may shape how T cells respond to infection and therapy

Short-term nutritional state can reshape T cell metabolism, with post-meal lipid metabolism enhancing T cell metabolic ...

Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform

Scientific Advisory Board (SAB) includes experts in the development and approved T-cell engager therapies, supporting CAPTN-3 ...
Nature

Blood test hints at breast-tumour response to treatment

A biomarker shows which people with certain types of breast cancer are more likely to respond to an immune-based therapy.
Nature

Long-lived immune cells show promise against cancer in world-first trial

The first clinical trial to test the tumour-fighting power of a stem-cell-like class of long-lived immune cells suggests that ...

Why this CAR T advance matters: Complete remissions without chemotherapy at doses as low as 250,000 cells/kg

Stem-cell memory T (TSCM) cells are a rare subset of immune cells with the ability to self-renew, persist long term, and ...

Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting

Presentation Date / Time : Friday, May 1, 2026 / 2:55 p.m. to 6:00 p.m. EDT ...

Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors

Pliant Therapeutics (Nasdaq: PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical trial of PLN-101095 in combination with ...